ArticleThe Journal of clinical investigation2026
EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer.
Bangwei Fang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.